Issue 46, 2015

A DT-diaphorase responsive theranostic prodrug for diagnosis, drug release monitoring and therapy

Abstract

A DT-diaphorase-activatable theranostic prodrug, which contains camptothecin, a self-immolative linker and a trigger group, has been developed for the detection of DT-diaphorase, tracking of drug release and selectively killing cancer cells over-expressed with DT-diaphorase. This strategy may offer a new approach for the development of enzyme-catalyzed theranostic anticancer therapeutics.

Graphical abstract: A DT-diaphorase responsive theranostic prodrug for diagnosis, drug release monitoring and therapy

Supplementary files

Article information

Article type
Communication
Submitted
13 Mar 2015
Accepted
01 May 2015
First published
04 May 2015

Chem. Commun., 2015,51, 9567-9570

A DT-diaphorase responsive theranostic prodrug for diagnosis, drug release monitoring and therapy

P. Liu, J. Xu, D. Yan, P. Zhang, F. Zeng, B. Li and S. Wu, Chem. Commun., 2015, 51, 9567 DOI: 10.1039/C5CC02149A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements